Zinc Incorporated Bovine Derived- Hydroxyappatite Xenograft in Immediately Placed Implant

NCT07187609 | Recruiting

• 1 other identifier: Zinc in immediate implant
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to evaluate Clinical and radiographic effect of zinc incorporated bovine derived hydroxyapatite xenograft and bovine hydroxyapatite xenograft alone for immediately placed implant

Conditions

Implant; Zinc Status

Keywords

bone grafts; Implant; zinc in corporated bovine drived hydroxyappatite

Outcome Measures

Primary Outcomes (1)

• Marginal bone loss

  Marginal bone loss was defined as the distance from the implant platform to the alveolar crest.

  9 months

Secondary Outcomes (1)

• densitometric gray scale value to measure bone density

  9 months

Study Arms (2)

Group I (control)

EXPERIMENTAL

patients will undergo immediate implant with bovine drived hydroxyapatite xenograft

Procedure: Immediate implant with bovine drived hydroxyapatite xenograft.

Group II (Test group)

EXPERIMENTAL

patients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft

Procedure: immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft

Interventions

Immediate implant with bovine drived hydroxyapatite xenograft. PROCEDURE

patients will undergo immediate implant with bovine drived hydroxyapatite xenograft.

Group I (control)

immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft PROCEDURE

patients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft

Group II (Test group)

Eligibility Criteria

• Age: 21 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Adult(male or female) patients between the ages of 21 -50 years who requiring the replacement of one or more non-restorable teeth in the mandible which will be indicated for extraction.
• Adequate bone dimensions at the implant site with ridge width of at least 6 mm, the availability of at least 3mm of sound subapical bone, the presence of an intact labial bone plate, and no evidance of periapical infection on cone beam computed tomography or clinically
• The peri-implant gaps larger than 1.5 mm will be included.
• All patients will be physically healthy with no medical history of any systemic disease.

You may not qualify if:

• Smokers.
• Patients with para functional habits such as bruxism and clenching
• Poorly controlled systemic diseases which preclude local anesthesia or surgical procedures
• Patients undergoing chemotherapy or radiotherapy and immuno-compromised patients.
• Pregnant /lactating women.
• Patients that are allergic to zinc
• Patients on antibiotic therapy in the pervious 6 months

Sponsors & Collaborators

• Suez Canal University: lead

Study Sites (1)

Suez canal university

Suez, Egypt

RECRUITING

Central Study Contacts

Ibrahim Montaser, General Dental Practitioner

CONTACT

0 10 66189289; pgs.230046@dent.suez.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: August 16, 2025
• First Posted: September 23, 2025
• Study Start: August 13, 2025
• Primary Completion: October 8, 2025
• Study Completion (Estimated): November 8, 2026
• Last Updated: September 23, 2025

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)